Biotech

ProMIS Neurosciences provided a corporate update to shareholders for the second quarter of 2017.

ProMIS Neurosciences (TSX:PMN) provided a corporate update to shareholders for the second quarter of 2017.
As quoted in the press release:

Commenting on the update, ProMIS Executive Chairman Eugene Williams stated: “We are pleased with the continued progress at ProMIS and remain confident that our monoclonal antibody programs focused on selectively targeting the toxic, prion-like forms of Amyloid beta may lead to best in class therapies and significant long-term value creation”.

Click here to read the full press release.

Source: www.newswire.ca

Featured

MARKETS

Markets
TSX20633.28-62.89
TSXV769.97-13.72
DOW32899.37-98.60
S&P 5004123.34-23.53
NASD12144.66-173.03
ASX7205.60-159.10

COMMODITIES

Commodities
Gold1883.86+0.34
Silver22.36+0.03
Copper4.25-0.04
Palladium2053.51+11.51
Platinum964.03+3.69
Oil110.61+2.35
Heating Oil4.00-0.04
Natural Gas7.98-0.80

DOWNLOAD FREE REPORTS

×